Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from ...

Key Takeaways Novo Nordisk's U.S.-listed shares lost ground Friday after a Phase 2a trial of the pharmaceutical firm’s latest ...

2024年3月15日，尽管Novo Nordisk（NYSE:NVO）的II期肥胖试验结果不尽如人意，TD Cowen仍维持其买入评级和155.00美元的目标价。该试验研究了公司的CB1阻断剂monlunabant，在16周时显示约6-7%的体重减轻。 这次更新未能达到预期的疗效和安全性，但未发现严重的神经精神不良事件。然而，接受monlunabant治疗的参与者出现轻度至中度神经精神副作用的情况 ...

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose.

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

诺和诺德公司股价今日出现显著下跌，在其肥胖药物monlunabant试验结果不如预期后暴跌超过4%。这一跌幅使得公司股价降至8月10日以来的最低点。

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...